Real-Life Efficacy and Tolerability of Lacosamide in Pediatric Patients Aged 4 Years or Older with Drug-Resistant Epilepsy
Annals of Child Neurology · 01.07.2023 · 31 (3) · 206-214
DOI: 10.26815/acn.2023.00073 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Child Neurology, erschienen am 01.07.2023. Verfasst von Shin Yun Byun und 6 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pusan National University.
Abstract (Originalsprache)
Purpose
The aim of this study was to evaluate the efficacy and safety of adjunctive lacosamide therapy in pediatric patients aged ≥4 years with drug-resistant epilepsy (DRE).
Methods
Medical records of children aged 4 to 19 years treated with lacosamide as adjunctive therapy for DRE were retrospectively reviewed. The patients were divided into two groups according to their age at the start of lacosamide treatment: group A (aged 4–15 years) and group B (aged 16–19 years). Changes in seizure frequency from baseline, adverse events, and the retention rate were evaluated at each follow-up visit.
Results
Sixty-two patients (33 males and 29 females) with a mean age of 11.4 years (range, 4 to 19) were included. The mean duration of follow-up was 20.1±12.9 months. The mean maintenance dose of lacosamide was 6.7±4.8 mg/kg/day. Forty-two patients (67.7%) were responders (≥50% reduction in seizures) with 19.4% (12/62) achieving freedom from seizures. The response rate did not differ significantly between groups A and B (67.6% vs. 68.0%, P=0.795) and was not affected by the concomitant use of sodium channel blockers. Significant independent factors associated with a good response to lacosamide treatment were a shorter duration of epilepsy (P=0.035) and fewer concomitant anti-seizure medications (P=0.002). Mild transient adverse events were observed in 20 patients (32.3%).
Conclusion
Lacosamide adjunctive therapy was efficacious and tolerated in children aged ≥4 years with DRE. Early use of lacosamide may be helpful for a good response to drug-resistant seizures.
Förderung
- Pusan National University
Zitieren
APA
Byun, S. Y., Kong, J., Lyu, S. Y., Nam, S. O., Kim, Y. M., Yeon, G. M., & Lee, Y. (2023). Real-Life Efficacy and Tolerability of Lacosamide in Pediatric Patients Aged 4 Years or Older with Drug-Resistant Epilepsy. Annals of Child Neurology, 31(3), 206-214. https://doi.org/10.26815/acn.2023.00073
Vancouver
Byun SY, Kong J, Lyu SY, Nam SO, Kim YM, Yeon GM, et al. Real-Life Efficacy and Tolerability of Lacosamide in Pediatric Patients Aged 4 Years or Older with Drug-Resistant Epilepsy. Annals of Child Neurology. 2023;31(3):206-214. doi:10.26815/acn.2023.00073
BibTeX
@article{Byun2023,
author = {Byun, Shin Yun and Kong, Juhyun and Lyu, Soo Young and Nam, Sang Ook and Kim, Young Mi and Yeon, Gyu Min and Lee, Yun-Jin},
title = {Real-Life Efficacy and Tolerability of Lacosamide in Pediatric Patients Aged 4 Years or Older with Drug-Resistant Epilepsy},
journal = {Annals of Child Neurology},
year = {2023},
volume = {31},
number = {3},
pages = {206--214},
doi = {10.26815/acn.2023.00073}
}
EUVIMED